Collectively, these in vitro and in vivo investigations confirm that CTHRC1 in CAFs upregulates LIF expression, thereby driving STAT3 pathway activation in pancreatic cancer cells and enhancing their proliferation and migration, positioning CTHRC1 as a potential diagnostic and therapeutic target in pancreatic cancer. This evidence concerns the gene LIF and pancreatic neoplasm.